Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early data support Anatare's needle-free insulin device

This article was originally published in Clinica

Executive Summary

Antares Pharma has reported promising preliminary trial data for its needle-free insulin injection system. All patients experienced a significant lowering of blood sugar shortly after each meal when their insulin was administered with the VISION injector, said the Exton, Philadelphia firm. Results showed that the firm's Medi-Jector VISION needle-free injection system average daily blood sugar levels by 17% - from a level of 184mg/dl to 152mg/dl - compared with conventional needle and syringe insulin delivery.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts